Marketdash
Back to News

uniQure Shares Slide as FDA Meeting Minutes Clarify Regulatory Roadblock

MarketDash Editorial Team
3 days ago
The gene therapy developer faces mounting uncertainty after the FDA confirmed that current data from AMT-130 trials likely won't support an accelerated approval pathway for its Huntington's disease treatment.

uniQure N.V. (QURE) is having a rough Thursday, with shares tumbling after the company disclosed final meeting minutes from the Food and Drug Administration that essentially threw cold water on its regulatory timeline.

The gene therapy company had met with the FDA in October for a pre-Biologics License Application discussion about AMT-130, its investigational treatment for Huntington's disease. Now the official minutes are in, and they're not encouraging.

The FDA made it clear that data from the Phase 1/2 studies of AMT-130 currently won't cut it as primary evidence to support a BLA submission. This aligns with what uniQure disclosed back in November, but seeing it formalized in the official minutes apparently reminded investors that this regulatory pathway just got a lot bumpier.

uniQure isn't giving up, though. The company is evaluating the feedback and plans to urgently request a follow-up meeting with the FDA sometime in the first quarter of 2026. That's several months away, which means extended uncertainty about when or if this treatment might reach the market.

Analysts Weigh In on the Surprise

William Blair didn't mince words in a Thursday note, calling the FDA's change in guidance "very surprising" given the numerous interactions uniQure has had with regulators since that November 2024 meeting. You'd think after all those conversations, everyone would be on the same page.

Analyst Sami Corwin pointed out another wrinkle: the trial design actually aligns with the FDA's recent plausible mechanism pathway publication and draft guidance on gene therapies for small populations. That guidance specifically says external controls may be appropriate in certain contexts, which makes the FDA's stance all the more puzzling.

William Blair's bottom line? Without a clear path to BLA submission or any sense of timing, uniQure stock will likely stay under pressure until investors get clarity on a reasonable and expeditious route to regulatory submission.

QURE Price Action: uniQure shares were down 11.24% at $22.60 at publication on Thursday.

Back to News

uniQure Shares Slide as FDA Meeting Minutes Clarify Regulatory Roadblock

MarketDash Editorial Team
3 days ago
The gene therapy developer faces mounting uncertainty after the FDA confirmed that current data from AMT-130 trials likely won't support an accelerated approval pathway for its Huntington's disease treatment.

uniQure N.V. (QURE) is having a rough Thursday, with shares tumbling after the company disclosed final meeting minutes from the Food and Drug Administration that essentially threw cold water on its regulatory timeline.

The gene therapy company had met with the FDA in October for a pre-Biologics License Application discussion about AMT-130, its investigational treatment for Huntington's disease. Now the official minutes are in, and they're not encouraging.

The FDA made it clear that data from the Phase 1/2 studies of AMT-130 currently won't cut it as primary evidence to support a BLA submission. This aligns with what uniQure disclosed back in November, but seeing it formalized in the official minutes apparently reminded investors that this regulatory pathway just got a lot bumpier.

uniQure isn't giving up, though. The company is evaluating the feedback and plans to urgently request a follow-up meeting with the FDA sometime in the first quarter of 2026. That's several months away, which means extended uncertainty about when or if this treatment might reach the market.

Analysts Weigh In on the Surprise

William Blair didn't mince words in a Thursday note, calling the FDA's change in guidance "very surprising" given the numerous interactions uniQure has had with regulators since that November 2024 meeting. You'd think after all those conversations, everyone would be on the same page.

Analyst Sami Corwin pointed out another wrinkle: the trial design actually aligns with the FDA's recent plausible mechanism pathway publication and draft guidance on gene therapies for small populations. That guidance specifically says external controls may be appropriate in certain contexts, which makes the FDA's stance all the more puzzling.

William Blair's bottom line? Without a clear path to BLA submission or any sense of timing, uniQure stock will likely stay under pressure until investors get clarity on a reasonable and expeditious route to regulatory submission.

QURE Price Action: uniQure shares were down 11.24% at $22.60 at publication on Thursday.